Stocks · News reference
OPKO Health (NASDAQ:OPK) sees Q3 sales of $131.000 million-$142.000 million vs $134.650 million analyst estimate.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-14 AccNo: 0001193125-26-352370 Size: 161 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits
Read original at edgarThe newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes
Read original at benzingaLongtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP)
Read original at benzingaGainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular session. The company's market cap stands at $936.3 million. As per the press release, Q2 earnings came out yesterday.
Read original at benzinga